Skip to content

VitaNova Life Sciences Corporation: 10-K filed 2025-07-24

What VitaNova Life Sciences Corporation reported in its annual report filed 2025-07-24 (fiscal FY 2025): 35 published measures, 72 facts as tagged in accession 0001683168-25-005368.

This filing

Form
10-K (annual report)
Filed
2025-07-24
Fiscal period
fiscal FY 2025
Accession
0001683168-25-005368 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VitaNova Life Sciences Corporation filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-04-302,256,251USD
At 2024-04-301,192,858USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-04-30347,567USD
At 2024-04-30136,920USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-04-301,908,684USD
At 2024-04-301,055,938USD
At 2023-04-30-59,215USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-05-01 to 2025-04-30850,746USD365
2023-05-01 to 2024-04-30140,865USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-05-01 to 2025-04-30192,774USD365
2023-05-01 to 2024-04-30-375,880USD366

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-05-01 to 2025-04-302,662,105USD365
2023-05-01 to 2024-04-30570,694USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-05-01 to 2025-04-30-3,000USD365
2023-05-01 to 2024-04-30960,188USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-04-30867,701USD
At 2024-04-3016,955USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-05-01 to 2025-04-3025,012,270shares365
2023-05-01 to 2024-04-3010,643,395shares366

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-05-01 to 2025-04-3025,012,270shares365
2023-05-01 to 2024-04-3010,643,395shares366

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-05-01 to 2025-04-300.03USD/shares365
2023-05-01 to 2024-04-300.01USD/shares366

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-05-01 to 2025-04-300.03USD/shares365
2023-05-01 to 2024-04-300.01USD/shares366

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-05-01 to 2025-04-30353,558USD365
2023-05-01 to 2024-04-3064,869USD366

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-05-01 to 2025-04-302,000USD365
2023-05-01 to 2024-04-301,000USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-05-01 to 2025-04-301,208,314USD365
2023-05-01 to 2024-04-30205,629USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-04-302,256,251USD
At 2024-04-301,192,858USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-05-01 to 2025-04-304,506USD365
2023-05-01 to 2024-04-300USD366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-04-30347,567USD
At 2024-04-30136,920USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-04-301,266,951USD
At 2024-04-300USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-05-01 to 2025-04-30367,396USD365
2023-05-01 to 2024-04-30172,082USD366

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-04-3044,247USD
At 2024-04-30132,873USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2024-05-01 to 2025-04-301,575,710USD365
2023-05-01 to 2024-04-30377,711USD366

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2024-05-01 to 2025-04-301,086,395USD365
2023-05-01 to 2024-04-30192,983USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-04-3025,012,270shares
At 2024-04-3025,012,270shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-04-30782,810USD
At 2024-04-30593,036USD
At 2023-04-308,728USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-04-301,012,971USD
At 2024-04-301,012,971USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2025-04-300USD
At 2024-04-300USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-05-01 to 2025-04-301,204,304USD365
2023-05-01 to 2024-04-30205,734USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-05-01 to 2025-04-30158,122USD365
2023-05-01 to 2024-04-3086,753USD366

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-05-01 to 2025-04-304,506USD365
2023-05-01 to 2024-04-300USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-05-01 to 2025-04-30-4,010USD365
2023-05-01 to 2024-04-30105USD366

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-05-01 to 2025-04-300USD365
2023-05-01 to 2024-04-300USD366

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2024-05-01 to 2025-04-300USD365
2023-05-01 to 2024-04-300USD366

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-05-01 to 2025-04-301,266,951USD365
2023-05-01 to 2024-04-300USD366

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-05-01 to 2025-04-30-88,626USD365
2023-05-01 to 2024-04-30132,873USD366

Inspect the source

Entity
VitaNova Life Sciences Corporation / CIK 0001699709
Captured
2026-09-21T17:23:55.214Z
SEC response SHA-256
cbbc169c744671a8d8af3ef9e33d6f01a860c1244f31147d1b245c430a85543c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001699709.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))